Previous 10 | Next 10 |
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma...
Gainers: VivoPower International (NASDAQ: VVPR ) +108% . Minerva Neurosciences (NASDAQ: NERV ) +43% . PCM (NASDAQ: PCMI ) +42% . Krystal Biotech (NASDAQ: KRYS ) +30% . NRC Group Holdings (NYSEMKT: NRCG ) +26% . India Globalization Capital (NYSEMKT: IGC ) +21% . Rekor Systems (R...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN LONDON and REDWOOD CITY, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma ...
Mereo BioPharma Group plc (NASDAQ: MREO ) announces positive preliminary data from a Phase 2b dose-ranging study, ASTEROID , evaluating BPS-804 (setrusumab) in patients with Type I, II or IV osteogenesis imperfect a, an inherited disorder also called "brittle bone disease" due to fr...
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of study to be available in fourth quarter 2019 A call for analysts and investor...
LONDON, May 03, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH, NASDAQ:MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that the Trustee of the Mereo BioPharma Group plc Employee Benefit Trust (the “Trust”), L...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. LONDON, April 29, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (N...
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announced that it will release prelim...
LONDON, April 24, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that, in connection with the completed merger with OncoMed Pharmaceuticals, Inc. (“OncoMed...
Unicorns are finally inbound. News broke that Lyft (LYFT) is prepping an IPO filing this coming week, which would put it on track for a late-March listing. Another "decacorn," Pinterest (PINIT), reportedly filed confidentially for an IPO expected around late June. Just one company submitted ...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutica...
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...